"I have consistently expressed my concern to the committee that I do not think requiring a reduction in price for a streamlined cost pathway is an appropriate way forward," said Medicines Australia chief executive Liz de Somer.
'If it is necessary for me to formally dissent in the final report, I will do so'
February 1, 2024 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the DayLatest Video
New Stories
-
'The truth is more that they are the heroes of every walk of life'
May 6, 2024 - - Latest News -
HTA review's final report now sits with Health Minister Mark Butler
May 6, 2024 - - Latest News -
The secrecy of the process was wrong, but the report is now the minister's to release
May 6, 2024 - - Latest News -
The Week in Review Podcast - 3 May
May 3, 2024 - - Podcast -
New data shows significant increase in the number of pharmacies supplying naloxone
May 3, 2024 - - Latest News -
CSL Seqirus secures local rights to new adrenaline nasal spray
May 3, 2024 - - Latest News -
Industry applauds funding commitment for National One Stop Shop for clinical trials
May 3, 2024 - - Latest News